AbbVie Inc. — SEC Form 4 Filings
SEC Form 4 Data
Track insider buying and selling activity for AbbVie Inc. (ABBV). Data sourced from SEC EDGAR Form 4 filings and analyzed by StoxPulse AI for significance.
11
$0.00 total
9
$25.3M total
1.2x
Neutral Signal
20
Form 4 transactions
Buy − Sell value
Sale · Feb 27, 2026
FALK · Buy
AbbVie Inc. insiders filed 20 Form 4 transactions in the period analyzed: 11 purchases totaling $0.00 and 9 sales totaling $25.3M. That puts the buy-to-sell ratio at 1.22, which we read as neutral on a directional basis.
The most active filer was Siatis Perry C with 4 transactions in this window. 19 of the 20 filings are flagged as routine — typically 10b5-1 scheduled trades rather than discretionary signals.
Form 4 filings are point-in-time disclosures and do not constitute investment advice. Routine sales under pre-arranged 10b5-1 plans should not be read as bearish.
| Insider | Title | Type | Shares | Price | Value | Date |
|---|---|---|---|---|---|---|
| FALK THOMAS J | Director | Buy | 1,118 | $0.00 | $0.00 | 2026-05-08 |
| WADDELL FREDERICK H | Director | Buy | 1,118 | $0.00 | $0.00 | 2026-05-08 |
| Roberts Rebecca B | Director | Buy | 1,118 | $0.00 | $0.00 | 2026-05-08 |
| RAPP EDWARD J | Director | Buy | 1,118 | $0.00 | $0.00 | 2026-05-08 |
| Quaggin Susan E | Director | Buy | 1,118 | $0.00 | $0.00 | 2026-05-08 |
| MEYER MELODY B | Director | Buy | 1,118 | $0.00 | $0.00 | 2026-05-08 |
| Hart Brett J | Director | Buy | 1,118 | $0.00 | $0.00 | 2026-05-08 |
| FREYMAN THOMAS C | Director | Buy | 1,118 | $0.00 | $0.00 | 2026-05-08 |
| Davis Jennifer L. | Director | Buy | 1,118 | $0.00 | $0.00 | 2026-05-08 |
| BURNSIDE WILLIAM H.L. | Director | Buy | 1,118 | $0.00 | $0.00 | 2026-05-08 |
| AUSTIN ROXANNE S | Director | Buy | 1,118 | $0.00 | $0.00 | 2026-05-08 |
| Purdue David Ryan | SVP, Controller | Sale | 5,230 | $233.56 | $1.2M | 2026-03-04 |
| Siatis Perry C | EVP, GC AND SECRETARY | Sale | 5,777 | $233.51 | $1.3M | 2026-03-02 |
| Siatis Perry C | EVP, GC AND SECRETARY | Sale | 10,291 | $234.66 | $2.4M | 2026-03-02 |
| Siatis Perry C | EVP, GC AND SECRETARY | Sale | 2,600 | $235.26 | $612K | 2026-03-02 |
| Crum Demetris D | EVP, CHIEF HR OFFICER | Sale | 1,594 | $232.08 | $370K | 2026-02-27 |
| Thakkar Roopal | EVP, R&D and CSO | Sale | 8,037 | $232.08 | $1.9M | 2026-02-27 |
| Michael Robert A. | CHAIRMAN OF THE BOARD AND CEO | Sale | 36,523 | $232.08 | $8.5M | 2026-02-27 |
| Stewart Jeffrey Ryan | EVP, CHIEF COMMERCIAL OFFICER | Sale | 23,812 | $232.08 | $5.5M | 2026-02-27 |
| Siatis Perry C | EVP, GC AND SECRETARY | Sale | 14,850 | $232.08 | $3.4M | 2026-02-27 |
Insider trading data for AbbVie Inc. (ABBV) is sourced directly from SEC Form 4 filings on the EDGAR database. Corporate insiders — including directors, officers, and shareholders owning more than 10% of the company — are legally required to report their transactions within two business days.
Insider purchases are often considered a bullish signal because executives are using their own money to buy shares, suggesting they believe the stock is undervalued. Insider sales, on the other hand, are more nuanced — they can reflect routine diversification plans (known as 10b5-1 plans), tax obligations, or genuine concerns about the company's outlook.
StoxPulse's AI system analyzes each ABBV insider transaction to determine whether it appears routine or notable. We track the buy/sell ratio, total transaction values, and patterns over time to provide a clear picture of insider sentiment for AbbVie Inc..
AI earnings, financials, news & more
Translate any filing into plain English
Disclaimer: Insider trading data for AbbVie Inc. (ABBV) is sourced from SEC Form 4 filings and is provided for informational purposes only. Insider transactions should not be the sole basis for investment decisions. Always consult a qualified financial advisor.
Join the waitlist to receive instant AI notifications when AbbVie Inc. insiders buy or sell shares.
Join the Waitlist